Health
Eyepoint Faces Setback as Amylyx Celebrates Success
By Editor • August 18, 2026 • 1 min read
Eyepoint's trial setback for Duravyu contrasts with Ocular Therapeutix's stock rise, while Novartis withdraws reimbursement plans for another new drug in Canada.
Read more